Temsirolimus

Cat. No. 5264

Temsirolimus C56H87NO16 [162635-04-3]

Price and Availability

For Temsirolimus pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Alternative Name: CCI-779

Chemical Name: Rapamycin 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]

Biological Activity

mTOR inhibitor; inhibits tumor growth in breast cancer cell lines (IC50 values are 1.6 and 4.3 nM for SKBr3 and BT474, respectively). Inhibits HIF-1α-mediated VEGF production in breast cancer cell lines (BT474 and MDA-MB-231). Directly inhibits serum and VEGF mediated endothelial cell proliferation and morphogenesis in vitro and vessel formation in vivo. Causes G1/S cell cycle arrest in multiple cancer cell lines. Antiangiogenic. Activates autophagy.

Licensing Information

Sold for research purposes under agreement from Pfizer Inc.

Technical Data

M.Wt:
1030.29
Formula:
C56H87NO16
Solubility:
Soluble to 100 mM in DMSO and to 100 mM in ethanol
Purity:
>98 %
Storage:
Store at -20°C
CAS No:
162635-04-3

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.

Certificate of Analysis / Product Datasheet / Safety Datasheet

References are publications that support the products' biological activity.

Galluzzi et al (2017) Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat.Rev.Drug.Discov.. PMID: 28529316.

Li et al (2013) The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells. Cancer Cell Int. 13. PMID: 23537100.

Wang et al (2012) Inhibition of mammalian target of rapamycin signaling by CCI-779 (temsirolimus) induces growth inhibition and cell cycle arrest in Cashmere goat fetal fibroblasts (Capra hircus). DNA Cell Biol. 31 1095. PMID: 22320865.

Del Bufalo et al (2006) Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 66 5549. PMID: 16740688.

Wu L et al (2005) Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res. 65 2825. PMID: 15805283.

If you know of a relevant reference for Temsirolimus please let us know.

Citations are publications that use Tocris products.

Do you know of a great paper that uses Temsirolimus from Tocris? If so please let us know.

View Related Products by Product Action

Keywords: Temsirolimus, supplier, Breast, cancer, mTOR, inhibitors, inhibits, rapamycin, kinases, suppresses, cell, tumour, tumor, growth, VEGF, Vascular, endothelial, growth, factor, CCI-779, Tocris Bioscience, mTOR Inhibitor products

Quick Order

Find multiple products by catalog number

divider line

Cancer Research Product Guide

Cancer Research Product Guide

Our Cancer Research Guide highlights over 750 products for cancer research. Request copy or view PDF today.

divider line

Kinase Inhibitor Toolbox

80 Kinase inhibitors
pre-dissolved in DMSO

Kinase Inhibitor Toolbox

Includes many of the latest kinase inhibitors to become commercially available. Covers a wide range of kinase targets including EGFR, MAPK and CDK.

divider line

Kinases Product Listing

Kinases Product Listing

Our Kinase listing highlights over 400 products for kinase research. Request copy or view PDF today.

divider line

Pain Research Product Guide

Pain Research Product Guide

Our Pain guide highlights over 280 products for Pain research. Request copy or view PDF today.

divider line

mTOR Signaling Pathway

mTOR Signaling Pathway

The mTOR complexes (mTORC1 and 2) respond to intra- and extracellular signals to mediate cell growth, proliferation and survival. View pathway or download PDF today.

divider line

New Products in this Area

HS 38

ATP-competitive inhibitor of DAPK and ZIPK

st-Ht31 P

Negative control for st-Ht31 (Cat. No. 6286)

st-Ht31

Inhibits PKA/AKAP interactions; cell permeable

P21d hydrochloride

Potent and selective Brk inhibitor

CVT 313

cdk2 inhibitor

TPPB

High affinity PKC activator; also APP modulator

JH 295

Irreversible Nek2 inhibitor

OXSI 2

Potent Syk kinase inhibitor; also inhibits assembly of NLRP3 inflammasomes

STK16-IN-1

Serine/threonine protein kinase 16 (STK16) inhibitor; also inhibits PI 3Kδ, PI 3Kγ and mTOR kinases.

AZ PFKFB3 26

Potent and selective PFKFB3 inhibitor

NCL 00017509

Potent and reversible NIMA related kinase 2 (Nek2) inhibitor

XMD 8-87

Potent Ack1/TNK2 inhibitor

SKI 178

Non-lipid sphingosine kinase 1 (SphK1) inhibitor

ML 315 hydrochloride

Inhibitor of Clk and DYRK kinases

Everolimus

mTOR inhibitor;immunosuppressant

PKI (5-24)

High affinity PKA inhibitor

TDZD 8

Selective non-ATP competitive inhibitor of GSK 3β

BI 605906

Selective IKKβ inhibitor

GSK 319347A

Potent and selective IKKε inhibitor

FRAX 597

Potent group I PAK inhibitor

MRT 68921 dihydrochloride

Potent ULK inhibitor; inhibits autophagy

AM 2394

Potent glucokinase activator; orally bioavailable

eCF 309

Potent mTOR inhibitor

Sign-up for new product e-alerts
divider line

Twitter Updates

Follow @Tocris on Twitter

Follow us on Twitter!

Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.